VPB1279 - Oxidative Stress Biomarkers and Their relevance to fatty Acid-Binding Protein in Stage-V Chronic Kidney Disease Patients on Hemodialysis

Tuesday, July 12, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Presenting Author(s)

Divya Sridharan

Medical student
Loyola University Medical Center
Maywood, Illinois, United States

Co-Author(s)

VB

Vinod Bansal

Doctor
Loyola University Medical Center
Maywood, Illinois, United States
FS

Fakiha Siddiqui

Doctor
Loyola University Medical Center
Maywood, Illinois, United States
Pranathi Karumanchi

Medical student
Loyola University Medical Center
Palatine, Illinois, United States
AO

Ameer Odeh

Medical student
Loyola University Medical Center
Maywood, Illinois, United States
OI

Omer Iqbal

Doctor
Loyola University Medical Center
Maywood, Illinois, United States
Bulent Kantarcioglu, MD

MD
Loyola University Chicago
Chicago, Illinois, United States
JF

Jawed Fareed, n/a

Professor
Loyola University Medical Center
MAYWOOD, Illinois, United States

Background: Oxidative stress plays a major role in the progression of kidney disease. Nitric Oxide (NO), malondialdehyde (MDA), nitrotyrosine, annexin V, myeloperoxidase (MPO), non-esterified fatty acids (NEFA), fatty acid binding protein (FABP) and inflammatory cytokines are commonly used biomarkers of oxidative stress in various clinical conditions.

Aims: The purpose of this investigation is to compare the levels of circulating oxidative stress biomarkers including L-FABP in stage V chronic kidney disease (CKD-V) patients on hemodialysis (HD) compared to normal healthy controls.

Methods: Blood samples were collected in sodium citrate tubes from stable patients with CKD-V who are treated at Loyola University Medical Center Outpatient Dialysis Unit. Normal human plasma (NHP) samples was commercially obtained. Sandwich enzyme-linked immunosorbent assay (ELISA) methods were utilized to evaluate plasma levels of NO, MDA, nitrotyrosine, annexin V, MPO, troponin, VEGF, NEFA, plasminogen activator inhibitor 1 (PAI-1),inflammatory cytokines and L-FABP.

Results: The CKD-V cohort showed a statistically significant elevation in the levels of annexin V (7.57 ± 5.24 ng/mL) NO (34.74 ± 19.74 pg/mL), and L-FABP (106,599 ± 176,729 pg/mL) compared to the NHP group. Lower levels of MPO (100.2 ± 19.28 mU/mL) and NEFA (0.56 ± 0.34 mEq/L) was observed in comparison to the NHP group (p < 0.05). L-FABP levels were significantly elevated, almost 20-fold higher in CKD-V patients compared to the NHP group. Spearman correlation revealed a negative correlation of L-FABP with NEFA ( r= -0.22; p < 0.05) and a positive correlation of L-FABP with nitrotyrosine (r = 0.36; p < 0.05) in the CKDV cohort.

Conclusion(s): These results suggest that as oxidative stress increases in chronic kidney disease patients, the rate of lipid peroxidation also increases, thereby converting NEFAs into lipoperoxides. As levels of these lipoperoxides increase, L-FABP levels also increase as a protective measure to excrete the toxic byproducts out of the body